Impact of high-dose chemotherapy on peripheral T-cell lymphomas

J. Rodriguez, M. Munsell, S. Yazji, F. B. Hagemeister, A. Younes, B. Andersson, S. Giralt, J. Gajewski, M. De Lima, D. Couriel, J. Romaguera, F. F. Cabanillas, R. E. Champlin, I. F. Khouri

    Research output: Contribution to journalArticle

    136 Scopus citations

    Abstract

    Purpose: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy. Patients and Methods: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation. Results: A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [Cl], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% Cl, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P < .001). A Pretransplant International Prognostic Index score of ≤ 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease. Conclusion: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin's lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.

    Original languageEnglish (US)
    Pages (from-to)3766-3770
    Number of pages5
    JournalJournal of Clinical Oncology
    Volume19
    Issue number17
    DOIs
    StatePublished - Sep 1 2001

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Impact of high-dose chemotherapy on peripheral T-cell lymphomas'. Together they form a unique fingerprint.

  • Cite this

    Rodriguez, J., Munsell, M., Yazji, S., Hagemeister, F. B., Younes, A., Andersson, B., Giralt, S., Gajewski, J., De Lima, M., Couriel, D., Romaguera, J., Cabanillas, F. F., Champlin, R. E., & Khouri, I. F. (2001). Impact of high-dose chemotherapy on peripheral T-cell lymphomas. Journal of Clinical Oncology, 19(17), 3766-3770. https://doi.org/10.1200/JCO.2001.19.17.3766